QR Pharma announces the start of a phase I clinical study for Bisnorcymserine
10:20 EDT 24 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
QR
Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company
committed to developing therapeutics with novel approaches for the
treatment of Alzheimer’s
disease (AD), Parkinson’s
disease (PD) and oth...
Other Sources for this Article
QR Pharma, Inc.
Maria Maccecchini, CEO
Tel: 610-727-3710
Maccecchini@qrpharma.com
www.qrpharma.com
More From BioPortfolio on "QR Pharma announces the start of a phase I clinical study for Bisnorcymserine"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
